BMC Pulmonary Medicine · 2022 · 20 citations · 22 references
Health ProfessionsRespiratory TherapyCritical Care Respiratory TherapyPulmonary Function TestingVentilator ManagementAcute Respiratory Distress Syndrome VentilationAcute Respiratory FailureMechanical VentilationOxygen TherapyRespiratory FailureRespiratory MonitoringAcute Hypoxemic Respiratory FailureHeart RateHigh-flow Nasal Cannula Oxygen TherapyHigh-flow Nasal Cannula SupportIntensive Care Unit MortalityIntubation-related HypoxemiaPulse OximetryRespiratory Rate
Abstract Background This study was designed to explore the early predictive value of the respiratory rate oxygenation (ROX) index modified by PaO 2 (mROX) in high-flow nasal cannula (HFNC) therapy in patients with acute hypoxemia respiratory failure (AHRF). Method Seventy-five patients with AHRF treated with HFNC were retrospectively reviewed. Respiratory parameters at baseline and 2 h after HFNC initiation were analyzed. The predictive value of the ROX (ratio of pulse oximetry/FIO 2 to respiratory rate) and mROX (ratio of arterial oxygen /FIO 2 to respiratory rate) indices with two variations by adding heart rate to each index (ROX-HR and mROX-HR) was evaluated. Results HFNC therapy failed in 24 patients, who had significantly higher intensive care unit (ICU) mortality and longer ICU stay. Both the ROX and mROX indices at 2 h after HFNC initiation can predict the risk of intubation after HFNC. Two hours after HFNC initiation, the mROX index had a higher area under the receiver operating characteristic curve (AUROC) for predicting HFNC success than the ROX index. Besides, baseline mROX index of greater than 7.1 showed a specificity of 100% for HFNC success. Conclusion The mROX index may be a suitable predictor of HFNC therapy outcomes at the early phase in patients with AHRF.
22